| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00280-013-2272-0 |
| P698 | PubMed publication ID | 23982118 |
| P50 | author | Moon-Woo Seong | Q40659041 |
| P2093 | author name string | Kyung Hae Jung | |
| Sun Young Kim | |||
| Sun-Young Kong | |||
| Sook Ryun Park | |||
| Yong Sang Hong | |||
| Hyeong-Seok Lim | |||
| Young-Iee Park | |||
| P2860 | cites work | New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 |
| FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic O | Q34565268 | ||
| Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial | Q34616772 | ||
| Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologi | Q34624438 | ||
| Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity | Q34627947 | ||
| Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). | Q35134370 | ||
| Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma | Q36593143 | ||
| Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group | Q36621749 | ||
| In-vitro schedule-dependent interaction between oxaliplatin and 5-fluorouracil in human gastric cancer cell lines | Q40301836 | ||
| Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts | Q40590595 | ||
| Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial | Q44012101 | ||
| Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer | Q44155889 | ||
| Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment | Q44820379 | ||
| Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma | Q44908377 | ||
| First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule | Q45154772 | ||
| Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer. | Q45928691 | ||
| Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group | Q46135615 | ||
| Phase II trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) as first-line treatment for advanced gastric cancer | Q46142122 | ||
| The CYP2A6*4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer | Q46796258 | ||
| Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study | Q46934509 | ||
| Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. | Q46976913 | ||
| P433 | issue | 5 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 953-964 | |
| P577 | publication date | 2013-08-28 | |
| P1433 | published in | Cancer Chemotherapy and Pharmacology | Q326137 |
| P1476 | title | Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer | |
| P478 | volume | 72 |
| Q86991704 | Associations between CYP2A6 polymorphisms and outcomes of adjuvant S-1 chemotherapy in patients with curatively resected gastric cancer |
| Q37685527 | Genotypes Affecting the Pharmacokinetics of Anticancer Drugs |
| Q55260834 | Trial Watch: Chemotherapy with immunogenic cell death inducers. |
Search more.